Cardiotoxicity of programmed cell death 1 receptor/programmed cell death ligand 1 inhibitors: a meta-analysis
10.3760/cma.j.cn114015-20190212-00136
- VernacularTitle:程序性细胞死亡1受体/程序性死亡配体1抑制剂的心脏毒性meta分析
- Author:
Xuejia QIU
1
;
Gexi CAO
1
;
Dongdong TIAN
1
;
Yue ZHANG
1
;
Yufei LIAN
1
Author Information
1. 河北省人民医院药学部，石家庄 050051
- Publication Type:Journal Article
- Keywords:
Antineoplastic agents, immunological;
Programmed cell death 1 receptor;
Cardiotoxicity;
Meta-analysis
- From:
Adverse Drug Reactions Journal
2020;22(4):221-226
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To systematically evaluate cardiotoxicity of programmed cell death 1 receptor (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors.Methods:Clinical trials of PD-1/PD-L1 inhibitor alone or in combination with other treatments for tumors were collected by searching related databases at home and abroad (up to March 2, 2019). The methodological quality of studies was evaluated using the internationally accepted Cochrane collaboration′s risk of bias assessment tool. A meta-analysis was performed using RevMan 5.3 software to compare the incidences of cardiotoxicity between PD-1/PD-L1 inhibitors (trial group) and placebo or other antineoplastic agents(control group).Results:A total of 10 randomized controlled trials (RCTs) were enrolled, 9 of which were about PD-1 inhibitor alone or in combination with other antineoplastic agents, and 1 of which was about PD-L1 inhibitor monotherapy. There were a total of 5 291 patients, including 3 022 in the trial group and 2 269 in the control group. Evaluation of the methodological quality for studies showed that 4 RCTs were at high risk of bias and the other 6 were at low risk of bias. The meta-analysis showed that the incidence of cardiotoxicity in the trial group was significantly higher than that in the control group, and the difference was statistically significant[1.13% (34/3 022) vs. 0.22% (5/2 269), RR=2.38, 95 %CI: 1.19 -4.78, P=0.01]. Conclusion:PD-1/PD-L1 inhibitors have the risk of causing heart related adverse events, which should be paid attention to in clinical application.
